{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:49:45Z","timestamp":1787579385450,"version":"build-2736575974"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The Briganti 2019 nomogram stratifies risk of lymph node involvement (LNI) in prostate cancer, reducing unnecessary pelvic lymph node dissection (PLND) during radical prostatectomy (RP). However the applicability of the nomogram in diverse populations remains under-explored, with only one external validation study performed in an Asian population to date. We aim to evaluate the performance of the nomogram in a large tertiary Asian institution.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective cohort study was conducted, with analysis of the cancer registry in our tertiary institution of all patients who underwent RP with PLND between 1988 and 2023. The Briganti 2019 nomogram score was retrospectively calculated for each patient, and post-operative data was analyzed to determine rates of LNI in order to determine the performance of the nomogram in our cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>437 patients were included, with a median Briganti score of 11.2% (IQR 3.9\u201328.5%). The mean number of lymph nodes excised per patient was 15.1\u00b112. 292 (66.8%) patients had a Briganti score greater than 7%, but only 8.6% were noted to harbor pN1 disease after RP. In our Asian cohort, the 2019 Briganti nomogram only had a moderate discriminatory ability with an area under the receiver operating characteristic curve (AUC) of 0.77. On multivariate analysis, independent predictors of LNI in our population included percentage of positive biopsy cores [Odds Ratio (OR) 1.02, 95%CI 1.01\u20131.04, p=0.01] and extraprostatic extension on MRI prostate (OR 3.00, 95%CI 1.20\u20137.56, p=0.02).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The Briganti 2019 nomogram, while effective in many settings, only had a moderate ability to identify patients with pN1 disease in our Asian cohort. With potential limitations in its generalizability to multiple populations, a re-evaluation of its thresholds and further calibration to other populations might be required.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1583806","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T04:10:48Z","timestamp":1748319048000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Real world prevalence of pelvic lymph node involvement in prostate cancer in Asia: do we need a rethink on normograms?"],"prefix":"10.3389","volume":"15","author":[{"given":"Rachel","family":"Lau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Jie","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khi Yung","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin Yuanming","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu\u00a0Guang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Mee","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nye Thane","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Tuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kae Jack","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lui Shiong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1097\/01.ju.0000049032.38743.c7","article-title":"Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure","volume":"169","author":"Bader","year":"2003","journal-title":"J Urol"},{"key":"B3","unstructured":"EAU guidelines on prostate cancer\n          \n          \n          \n          2024"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.3390\/cancers15061683","article-title":"Comparison of four validated nomograms (Memorial sloan kettering cancer center, Briganti 2012, 2017, and 2019) predicting lymph node invasion in patients with high-risk prostate cancer candidates for radical prostatectomy and extended pelvic lymph node dissection: clinical experience and review of the literature","volume":"15","author":"Di Pierro","year":"2023","journal-title":"Cancers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.10.044","article-title":"Updated nomogram predicting lymph node invasion in patients with prostate cancer\u00a0undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores","volume":"61","author":"Briganti","year":"2012","journal-title":"Eur Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.03.049","article-title":"Development and internal validation of a novel model to identify the candidates for extended pelvic lymph node dissection in prostate cancer","volume":"72","author":"Gandaglia","year":"2017","journal-title":"Eur Urol"},{"key":"B7","unstructured":"Prostate cancer nomograms: dynamic prostate cancer nomogram: coefficients | Memorial sloan kettering cancer center\n          \n          \n          2025"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.10.012","article-title":"A novel nomogram to identify candidates for extended pelvic lymph node dissection among patients with clinically localized prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies","volume":"75","author":"Gandaglia","year":"2019","journal-title":"Eur Urol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.prnil.2023.07.004","article-title":"Prostate cancer nomograms and their application in Asian men: a review","volume":"12","author":"Panaiyadiyan","year":"2024","journal-title":"Prostate Int"},{"key":"B10","doi-asserted-by":"publisher","first-page":"8089","DOI":"10.3390\/ijerph17218089","article-title":"Impact of gene\u2013environment interactions on cancer development","volume":"17","author":"Mbemi","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-021-01954-4","article-title":"External validation of the Briganti 2019 nomogram to identify candidates for extended pelvic lymph node dissection among patients with high-risk clinically localized prostate cancer","volume":"26","author":"Fukagawa","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"847.e9","DOI":"10.1016\/j.urolonc.2020.04.011","article-title":"External validation of the Briganti nomogram predicting lymph node invasion in patients with intermediate and high-risk prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies: A European multicenter study","volume":"38","author":"Diamand","year":"2020","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.03.023","article-title":"External validation of the 2019 Briganti nomogram for the identification of prostate cancer patients who should be considered for an extended pelvic lymph node dissection","volume":"78","author":"Gandaglia","year":"2020","journal-title":"Eur Urol"},{"key":"B14","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3390\/life11060479","article-title":"External validation of the Briganti nomogram to predict lymph node invasion in prostate cancer\u2014Setting a new threshold value","volume":"11","author":"Ma\u0142kiewicz","year":"2021","journal-title":"Life"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.829515\/full","article-title":"External validation and comparison of two nomograms predicting the probability of lymph node involvement in patients subjected to robot-assisted radical prostatectomy and concomitant lymph node dissection: A single tertiary center experience in the MRI-era","volume":"9","author":"Frego","year":"2022","journal-title":"Front Surg"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/bju.v128.2","article-title":"External validation of the Memorial Sloan Kettering Cancer Centre and Briganti nomograms for the prediction of lymph node involvement of prostate cancer using clinical stage assessed by magnetic resonance imaging","volume":"128","author":"Soeterik","year":"2021","journal-title":"BJU Int"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v110:6","article-title":"Differences in prognostic factors and survival among white and Asian men with prostate cancer, California, 1995-2004","volume":"110","author":"Robbins","year":"2007","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12301-023-00366-2","article-title":"Endogenous testosterone density associates with predictors of tumor upgrading and disease progression in the low through favorable intermediate prostate cancer risk categories: analysis of risk factors and clinical implications","volume":"29","author":"Porcaro","year":"2023","journal-title":"Afr J Urol"},{"key":"B19","article-title":"Lifestyle determinants of 5alpha-reductase metabolites in older African-American, white, and Asian-American men","volume":"10","author":"Wu","year":"2001","journal-title":"Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/ajhb.22482","article-title":"Testosterone concentrations in young healthy us versus Chinese men","volume":"26","author":"Xu","year":"2014","journal-title":"Am J Hum Biol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3390\/nu13010259","article-title":"Association of testosterone-related dietary pattern with testicular function among adult men: A cross-sectional health screening study in Taiwan","volume":"13","author":"Kurniawan","year":"2021","journal-title":"Nutrients"},{"key":"B22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.prnil.2022.03.004","article-title":"Prostate diseases and microbiome in the prostate, gut, and urine","volume":"10","author":"Miyake","year":"2022","journal-title":"Prostate Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2000069","article-title":"Racial differences in genomic profiling of prostate cancer","volume":"383","author":"Mahal","year":"2024","journal-title":"New Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"196","DOI":"10.21037\/tau.2020.02.21","article-title":"Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030","volume":"9","author":"Cai","year":"2020","journal-title":"Transl Androl Urol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(20000101)85:1<60::AID-IJC11>3.0.CO;2-B","article-title":"International trends and patterns of prostate cancer incidence and mortality","volume":"85","author":"Hsing","year":"2000","journal-title":"Int J Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","article-title":"Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for initial staging of intermediate- to high-risk prostate cancer: A systematic review and meta-analysis","volume":"84","author":"Chow","year":"2023","journal-title":"Eur Urol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.3390\/cancers16091777","article-title":"Seeing is believing\u201d: additive utility of 68Ga-PSMA-11 PET\/CT in prostate cancer diagnosis","volume":"16","author":"Chin","year":"2024","journal-title":"Cancers"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.05.006","article-title":"External validation and addition of prostate-specific membrane antigen positron emission tomography to the most frequently used nomograms for the prediction of pelvic lymph-node metastases: an international multicenter study","volume":"80","author":"Meijer","year":"2021","journal-title":"Eur Urol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers3043773","article-title":"Biomarkers in prostate cancer epidemiology","volume":"3","author":"Verma","year":"2011","journal-title":"Cancers"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1583806\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T04:10:50Z","timestamp":1748319050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1583806\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":29,"alternative-id":["10.3389\/fonc.2025.1583806"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1583806","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"article-number":"1583806"}}